-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
SourceGuanlan Pharmaceutical
On February 26, Nuocheng Jianhua announced that its new drug clinical trial application for its new Tyrosine Kinase 2 (TYK2) inhibitor ICP-332 has been accepted by the China National Medical Products Administration (NMPA).
TYK2 is a member of the Janus kinase (JAK) family of proteins.
ICP-332 is a more efficient and selective new type of TYK2 inhibitor, with strong inhibitory activity on TYK2.
According to the press release, the ICP-332 clinical trial application was accepted by NMPA, and it is expected to become Nuocheng Jianhua's fifth innovative drug to enter the clinical stage.
Nuocheng Jianhua was founded in 2015 by Dr.